Antimicrobial Resistance Surveillance Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

AMR surveillance encompasses the systems, consumables, and services that detect, monitor, and report antimicrobial-resistant organisms across clinical, veterinary, food, and environmental settings. In 2025 the market sits near USD 6.55 billion, with most private-sector forecasts clustering between USD 6.24B and USD 6.67B and projecting mid-single-digit annual growth. Demand is structural rather than cyclical, tied to rising resistance rates and the institutionalization of surveillance in national health systems.

• •2025 market value approximately USD 6.55 billion; compound annual growth rate around 5.82%.
• •Scope spans diagnostics, lab automation, bioinformatics software, and surveillance services.
• •No single official government agency publishes a commercial market size; estimates come from private research firms.

Government-led national action plans against AMR, particularly in the U.S., EU, UK, and parts of Asia-Pacific, are the principal demand catalyst, funding laboratory upgrades and data-reporting mandates. Rising infection rates of multidrug-resistant pathogens and the expansion of antimicrobial stewardship programs in hospitals are pulling diagnostic and IT solutions into routine care. Technological progress in next-generation sequencing, PCR-based resistance panels, and cloud-enabled surveillance platforms is lowering turnaround times and making large-scale monitoring feasible.

• •National AMR action plans and public funding for One Health surveillance programs.
• •Increasing prevalence of multidrug-resistant infections in hospital and community settings.
• •Adoption of molecular diagnostics, whole-genome sequencing, and AI-assisted resistance prediction.

By solution type, the market splits into diagnostic kits and instruments, laboratory automation, surveillance software, and services such as data management and consulting. By end user, hospital and clinical laboratories dominate, followed by public health agencies, research institutes, and veterinary/food safety labs. North America leads on spending and installed base, Europe follows on the strength of coordinated EU-wide surveillance, while Asia-Pacific is the fastest-growing region as countries such as China, India, and Japan expand national resistance networks.

• •Diagnostic products (kits, reagents, instruments) hold the largest revenue share; software and services growing fastest.
• •North America is the largest regional market; Asia-Pacific is projected to post the highest growth rate.
• •Human clinical surveillance is the leading application; veterinary and environmental surveillance are growing segments.

What are the recent trends and outlook?

Genomic surveillance is shifting from targeted PCR panels toward whole-genome sequencing for routine resistance typing, supported by falling sequencing costs and cloud bioinformatics. Integration of AMR surveillance with broader infectious-disease reporting, antimicrobial stewardship dashboards, and One Health data streams is becoming a procurement priority for public-health agencies. Over the medium term, expect stronger regulatory mandates on resistance reporting, more public-private data partnerships, and consolidation among smaller molecular diagnostics vendors as the market matures toward integrated surveillance platforms.

• •Move from phenotypic and PCR testing toward sequencing-based, real-time genomic surveillance.
• •Tightening of mandatory resistance reporting and One Health data integration requirements.
• •Likely consolidation among smaller diagnostics vendors as platforms seek end-to-end surveillance offerings.